SARC041: Study of Abemaciclib Versus Placebo in Patients With Advanced Dedifferentiated Liposarcoma
Condition(s):Advanced Dedifferentiated LiposarcomaLast Updated:January 12, 2023Recruiting
Hide Studies Not Open or Pending
Condition(s):Advanced Dedifferentiated LiposarcomaLast Updated:January 12, 2023Recruiting
Condition(s):Dedifferentiated LiposarcomaLast Updated:April 14, 2015Withdrawn
Condition(s):Advanced Dedifferentiated Liposarcoma; Locally Advanced Dedifferentiated Liposarcoma; Metastatic Dedifferentiated Liposarcoma; Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8; Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8; Unresectable Dedifferentiated LiposarcomaLast Updated:January 23, 2023Not yet recruiting
Condition(s):Leiomyosarcoma; LiposarcomaLast Updated:November 28, 2022Recruiting
Condition(s):Soft Tissue SarcomaLast Updated:January 4, 2023Active, not recruiting
Condition(s):Liposarcoma, DedifferentiatedLast Updated:January 13, 2023Recruiting
Condition(s):Dedifferentiated LiposarcomaLast Updated:September 14, 2021Completed
Condition(s):Adult Patients With Unresectable Locally Advanced or Metastatic, Relapsed/Refractory Dedifferentiated LiposarcomaLast Updated:January 25, 2021Terminated
Condition(s):Liposarcoma; Malignant Peripheral Nerve Sheath Tumors; Alveolar Soft Part Sarcoma; Ewing Sarcoma; SarcomaLast Updated:November 27, 2020Withdrawn
Condition(s):Dedifferentiated LiposarcomaLast Updated:January 23, 2023Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.